Is there a role for differentiating therapy in non-APL AML?

@article{Koeffler2010IsTA,
  title={Is there a role for differentiating therapy in non-APL AML?},
  author={H Phillip Koeffler},
  journal={Best practice & research. Clinical haematology},
  year={2010},
  volume={23 4},
  pages={503-8}
}
Differentiation therapy with all-trans retinoic acid has been a very successful therapeutic strategy in acute promyelocytic leukemia (APL), but the value of differentiation therapy in acute myeloid leukemia (AML) remains to be determined. A number of current treatments, such as tyrosine kinase inhibitors, cytokines, and epigenetic agents, induce differentiation of leukemic cells to some extent, but differentiation is not the main goal of these treatments. Forcing expression of certain… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

The Pax5 fusion product Pax5-C20orf112 causes downregulation of pre-B cell receptor genes and induces differential proliferation patterns in B-lymphoblastic cell lines

  • D Nowak, N Kawamata, B Niebuhr, V Nowak, M Mossner, RR Nahar
  • Blood
  • 2009

Similar Papers

Loading similar papers…